Myeloid Leukemia News and Research

RSS

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

Powerful data-sifting algorithms help untangle complex genetics of cancer

Powerful data-sifting algorithms developed by computer scientists at Brown University are helping to untangle the profoundly complex genetics of cancer.

2 May 2013

Genomics-based testing could change recommended course of treatment for endometrial cancer

The most in-depth look yet at endometrial cancer shows that adding genomics-based testing to the standard diagnostic workup could change the recommended course of treatment for some women.

2 May 2013

Research findings pave the way for developing better treatments for AML

A team of researchers led by Washington University School of Medicine in St. Louis has identified virtually all of the major mutations that drive acute myeloid leukemia, a fast-growing blood cancer in adults that often is difficult to treat.

2 May 2013

Findings set the stage for identifying potential new drug targets, treatment strategies for AML

nvestigators for The Cancer Genome Atlas Research Network have detailed and broadly classified the genomic alterations that frequently underlie the development of acute myeloid leukemia, a deadly cancer of the blood and bone marrow.

2 May 2013

Details about genomic landscapes of AML and endometrial cancer revealed

Two studies from The Cancer Genome Atlas program reveal details about the genomic landscapes of acute myeloid leukemia and endometrial cancer.

2 May 2013

BioLineRx starts enrollment in Phase I/II trial of BL-8020 for treatment of HCV

BioLineRx, a biopharmaceutical development company, announced today enrollment of the first patient in a Phase I/II trial for BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus.

29 Apr 2013

Increasing unsustainable prices for leukemia drugs represent larger issue across all cancers

The increasing cost of treatments for chronic myeloid leukemia (CML) in the United States has reached unsustainably high levels and may be leaving many patients under- or untreated because they cannot afford care, according to a Blood Forum article supported by nearly 120 CML experts from more than 15 countries on five continents and published online today in Blood, the Journal of the American Society of Hematology (ASH).

26 Apr 2013

Study identifies potential drug targets that interfere with cancer metabolism

A massive study analyzing gene expression data from 22 tumor types has identified multiple metabolic expression changes associated with cancer.

22 Apr 2013

Phase IIa study shows safety and efficacy of BL-7040 in treating ulcerative colitis

BioLineRx, a biopharmaceutical development company, announced today positive Phase IIa results for BL-7040, an orally available drug for treating inflammatory bowel disease.

17 Apr 2013

BioLineRx gets regulatory approvals in US to start BL-8040 Phase IIa trial for treatment of AML

BioLineRx, a biopharmaceutical development company, announced today that it has received all necessary regulatory approvals in the US to commence a Phase IIa trial for BL-8040, for the treatment of Acute Myeloid Leukemia.

11 Apr 2013

MD Anderson professor to receive award for clinical research excellence at AACR meeting

Hagop Kantarjian, M.D., chair and professor in The University of Texas MD Anderson Cancer Center's Department of Leukemia, will be honored for clinical research excellence at the AACR Annual Meeting 2013, April 6-10.

9 Apr 2013

Hebrew University professor wins 2013 Award for Outstanding Achievement in Chemistry in Cancer Research

The American Association for Cancer Research has chosen Prof. Alexander Levitzki of the Hebrew University of Jerusalem as the winner of its 2013 Award for Outstanding Achievement in Chemistry in Cancer Research.

9 Apr 2013

American Society of Hematology announces first recipients of ASH Bridge Grants

The American Society of Hematology, the world's largest professional organization dedicated to the causes and treatment of blood disorders, today announced the first recipients of the ASH Bridge Grants, a new award program designed to help hematologists continue their critical blood disease research amid severe funding reductions for the National Institutes of Health.

9 Apr 2013

Media outlets examine reaction to India's Supreme Court ruling on Novartis patent case

"In a decisive victory for India's pharmaceutical industry, India's Supreme Court rejected Novartis' patent application for the cancer drug Glivec on Monday, ending a seven-year battle by the Swiss drug maker to get a patent in India on its powerful leukemia drug," Time reports (Mahr, 4/1).

3 Apr 2013

Investigators examine effectiveness of probiotics for cancer treatment

One may not think of probiotics -- like those found in yogurt that promote good digestive health -- as a weapon used in the fight against cancer. But that is the focus of investigators at The Cancer Institute of New Jersey, who are examining the effectiveness of probiotics as they relate to the outcomes of bone marrow transplant for patients with blood cancers.

21 Mar 2013

Researchers complete phase II clinical trial of dasatinib for patients with higher-risk MDS

Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides.

21 Mar 2013

Myeloid Leukemia News and Research

Powerful data-sifting algorithms help untangle complex genetics of cancer

Genomics-based testing could change recommended course of treatment for endometrial cancer

Research findings pave the way for developing better treatments for AML

Findings set the stage for identifying potential new drug targets, treatment strategies for AML

Details about genomic landscapes of AML and endometrial cancer revealed

BioLineRx starts enrollment in Phase I/II trial of BL-8020 for treatment of HCV

Increasing unsustainable prices for leukemia drugs represent larger issue across all cancers

Study identifies potential drug targets that interfere with cancer metabolism

Phase IIa study shows safety and efficacy of BL-7040 in treating ulcerative colitis

BioLineRx gets regulatory approvals in US to start BL-8040 Phase IIa trial for treatment of AML

MD Anderson professor to receive award for clinical research excellence at AACR meeting

Hebrew University professor wins 2013 Award for Outstanding Achievement in Chemistry in Cancer Research

American Society of Hematology announces first recipients of ASH Bridge Grants

Media outlets examine reaction to India's Supreme Court ruling on Novartis patent case

Investigators examine effectiveness of probiotics for cancer treatment

Researchers complete phase II clinical trial of dasatinib for patients with higher-risk MDS

Research: Decreased levels of vitamin D may influence smokers to develop tobacco-related cancer

Targeting Mer receptors sensitize AML and ALL to chemotherapies

Stem cell transplantation could be delayed in acute myeloid leukemia

Chroma Therapeutics, CTI announce results from tosedostat Phase 2 study on AML

Industry Focus eBook - Life Science Microscopy (2nd Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News